newsfilter
← Latest News
GlobeNewswire·

Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)

  • Cogent Biosciences announced FDA acceptance of its New Drug Application for bezuclastinib in NonAdvanced Systemic Mastocytosis patients.
  • The FDA assigned a PDUFA target action date of December 30, 2026, for the bezuclastinib NonAdvSM submission.
  • The FDA stated there is no plan to hold an advisory committee meeting nor have identified any potential review issues for this application.
  • Pivotal SUMMIT trial results showed clinically meaningful improvements across primary and key secondary endpoints with continued deepening of symptomatic relief over 48 weeks.
  • Data indicated bezuclastinib benefits patients with high unmet need, improves bone mineral density, shows evidence of disease modification, and demonstrates a favorable safety profile for chronic use.
  • The company expects to complete the NDA submission for bezuclastinib in Gastrointestinal Stromal Tumors in April 2026, with the indication holding Breakthrough Therapy Designation under Real-Time Oncology Review.
  • The NDA submission for bezuclastinib in Advanced Systemic Mastocytosis remains on track for the first half of 2026.
  • Bezuclastinib is a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation and other KIT exon 17 mutations associated with systemic mastocytosis and GIST.
  • Cogent Biosciences is also developing a portfolio of novel therapies targeting mutations in ErbB2, PI3Kα, KRAS, and JAK2.